Preparation and preliminary biological evaluation of Lu-177 labeled somatostatin analogue DOTA-Pasireotide.

fei liu,hua zhu,chiyi xiong,chun li,zhi yang

2015-01-01

Journal of Nuclear Medicine

Abstract:1114 Objectives Octreotide and its derivatives have been widely used for SSTR positive tumors therapy, however, they only have high affinity of SSTR 2 among the five somatostatin receptors[1, 2]. Recently, Pasireotide was reported to have a better binding affinity of SSTR 1, 3, 5 and similar affinity of SSTR 2 compared with Octreotide[3, 4].The purpose of this work was to develop a new somatostatin analogue Pasireotide labeled by 177Lu to explore the possibility of its usage as a diagnostic and therapeutic radiopharmaceutical for neuroendocrine tumors and peptide receptor radionuclide therapy (PRRNT). Methods Cyclic peptide amide DOTA-Pasireotide was synthesized and radiolabeled with 177Lu to yield 177Lu-DOTA-Pasireotide (Figure.1). The precursor DOTA-Pasireotide was labeled with 177Lu in sodium acetate buffer (pH 4.0) by heating at 100 °C for 15 min and the products were determained by Radio-ITLC and radio-HPLC. In vitro stability experiments was taken in 5% human serum albumin, NaAc (pH 5.5) and PBS (pH 7.4) at room temperature (25 °C) for about 120 hours of incubation. After 12.95 MBq of 177Lu-DOTA-Pasireotide was injected intravenously to BALB/c nude mice bearing human HT29 colon tumors via tail vein, the SPECT/CT images were taken 2 h, 4 h, 8 h after radiotracer injection. Results 177Lu was radiolabeled with DOTA-Pasireotide in 98% radiochemical yield as determined by radio-TLC and radio-HPLC. In vitro stability experiments showed in 120 hours 177Lu-DOTA-Pasireotide was stable in 5% human serum albumin, NaAc (pH 5.5) and PBS (pH 7.4). In vivo, the HT29 cell xenograft tumors uptake of 177Lu-DOTA-Pasireotide were clearly visualized by 8 h postinjection. Conclusions We described the Radio-synthesis and characterization of 177Lu-DOTA-Pasireotide. It’s found to have high labeling efficiencies, short labeling time and high tumor cell uptakes. In brief, 177Lu-DOTA-Pasireotide may be useful both for cancer diagnostic and therapeutic applications. Research Support Supported by grant #81172083, grant #81371592 and grant #81401467 from the National Natural Science Foundation of China and by #7132040 from the Beijing Municipal Natural Science Foundation of China.